// App-Quantinova.ai

521 : Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane in the Canadian cancer trials Group MA.27.

Researchers

Presenter

  • Kathrin Strasser-Weippl

Principal Investigators

  • Gautam Sudan

  • Ravi Ramjeesingh

  • Lois E. Shepherd

  • Joyce O'Shaughnessy

  • Bingshu E. Chen

  • Wendy R. Parulekar

  • Pedro Emanuel Rubini Liedke

  • Paul E. Goss

Medical Centers

  • Wilheminen Hospital, Vienna, Austria

  • Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada

  • Nova Scotia Cancer Centre, Department of Medicine, Dalhousie University, Nova Scotia, NS, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

  • Baylor University Medical Center, Texas Oncology, Dallas, TX

  • NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Kingston, ON, Canada

  • Hospital De Clinicas de Porto Alegre, Porto Alegre RS, Brazil

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

Locations

  • United States

  • Canada

  • Brazil

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Anastrozole

  • Exemestane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved